

RELEVANCE OF BREAST CANCER CELL LINES AS MODELS FOR BREAST TUMOURS: AN UPDATE.
Marc Lacroix, Guy Leclercq
Breast Cancer Research and Treatment (2004) 83, 249-289
The number of available breast cancer cell (BCC) lines is small, and
only a very few of them have been extensively studied. Whether they are representative of the tumours
from which they originated remains a matter of debate. Whether their diversity mirrors the well-known
inter-tumoral heterogeneity is another essential question. While numerous similarities have long been
found between cell lines and tumours, recent technical advances, including the use of micro-arrays and
comparative genetic analysis, have brought new data to the discussion. This paper presents most of the
BCC lines that have been described in some detail to date. It evaluates the accuracy of the few of them
widely used (MCF-7, T-47D, BT-474, SK-BR-3, MDA-MB-231, Hs578T) as tumour models. It is concluded that
BCC lines are likely to reflect, to a large extent, the features of cancer cells in vivo. The
importance of oestrogen receptor-alpha (gene ESR1) and Her-2/neu (ERBB2) as classifiers
for cell lines and tumours is underlined. The recourse to a larger set of cell lines is suggested since
the exact origin of some of the widely used lines remains ambiguous. Investigations on additional lines
is expected to improve our knowledge of BCC and of the dialogue that these maintain with their surrounding
normal cells in vivo.
Summary
1. Presentation of BCC lines - The question of representativeness
1.1) Multiplicity and variability of BCC lines
A) Distinctive features of BCC lines
B) BCC lines series
"HCC (Hamon Cancer Centre) series"
D) BCC lines from breast cancer patients with germ line mutations
E) The specificity of inflammatory breast cancer
1.2) The problem of BCC lines representativeness
2. Phenotype and invasiveness-based studies of BCC lines and tumours
2.1) Phenotype and invasiveness-based BCC line classification
A) Steroid receptor status and the bias in BCC line isolation
B) Distinct phenotypes - The "epithelial-mesenchymal transition" (EMT) hypothesis
C) Extended marker analysis
2.2) Analysis of breast tumours - Markers and grade - Comparison with cell lines
2.3) Macroscopic homogeneity of breast tumours - Stable "portrait" during progression
A) Progression to invasiveness and markers/grade
B) Recurrence, metastasis
2.4) Concluding remarks on phenotype studies
3. Genetic studies on BCC lines and tumours
3.1) Karyotype and cytogenetic studies on BCC lines and tumours
3.2) Extension of genetic analyses: micro-array studies
C) Comparison of genetic profiles of BCC lines and tumours
3.3) Epigenetic alterations - Hypermethylation
4. Dialogue between tumour cells and their cellular environment
5. Tumourigenicity of BCC lines in animal models
Conclusion
To which extent are individual tumours genetically and phenotypically heterogeneous?
Do BCC cultured in vitro maintain the characteristics that they had in tumours?
Do the panel of widely used BCC lines accurately reflect the variety of tumour phenotypes?
Cell lines examined:
- "21-series"
- AU565 / AU-565 / AU 565
- BOT2 / BOT-2 / BOT 2
- BRC230 / BRC-230 / BRC 230
- BrCaMZ01 / BrCa-MZ-01 / BrCa MZ 01
- BrCaMZ02 / BrCa-MZ-02 / BrCa MZ 02
- BSMZ
- BT20 / BT-20 / BT 20
- BT474 / BT-474 / BT 474
- BT483 / BT-483 / BT 483
- BT549 / BT-549 / BT 549
- CAL18A / CAL-18A / CAL 18A
- CAL18B / CAL-18B / CAL 18B
- CAL51 / CAL-51 / CAL 51
- CAMA1 / CAMA-1 / CA-MA-1 / CAMA 1 / CA MA 1
- DU4475/ DU-4475 / DU 4475
- EFM19 / EFM-19 / EFM 19
- EP
- EVSAT / EVSA-T / EVSA T
- GI101 / GI-101 / GI 101
- GCS
- HBL100 / HBL-100 / HBL 100
- "HCC-series"
- HDQP1 / HDQ-P1 / HDQ P1
- HH315 / HH-315 / HH 315
- HH375 / HH-375 / HH 375
- "HMT-series"
- Hs578T / Hs578-T / Hs-578T / Hs 578T / Hs-578-T / Hs 578 T
- Ia270 / Ia-270 / Ia 270
- IBEP1 / IBEP-1 / IBEP 1
- IBEP2 / IBEP-2 / IBEP 2
- IBEP3 / IBEP-3 / IBEP 3
- IIBBRG / IIB-BRG / IIB-BR-G / IIB BRG / IIB BR G
- JCK
- KPL1 / KPL-1 / KPL 1
- KPL3C / KPL-3C / KPL 3C
- KPL4 / KPL-4 / KPL 4
- LCC15MB / LCC15-MB / LCC15 MB
- MA11 / MA-11 / MA 11
- MAST
- MaTu / Ma-Tu / Ma Tu / MATU / MA TU
- MCF7 / MCF-7 / MCF 7
- MDAMB134 / MDA-MB134 / MDAMB-134 / MDA-MB-134 VI / MDA134 / MDA-134 / MDA 134 / MDA MB 134
- MDAMB157 / MDA-MB157 / MDAMB-157 / MDA-MB-157 / MDA157 / MDA-157 / MDA 157 / MDA MB 157
- MDAMB175 / MDA-MB175 / MDAMB-175 / MDA-MB-175 VII / MDA175 / MDA-175 / MDA 175 / MDA MB 175
- MDAMB231 / MDA-MB231 / MDAMB-231 / MDA-MB-231 / MDA231 / MDA-231 / MDA 231 / MDA MB 231
- MDAMB330 / MDA-MB330 / MDAMB-330 / MDA-MB-330 / MDA330 / MDA-330 / MDA 330 / MDA MB 330
- MDAMB361 / MDA-MB361 / MDAMB-361 / MDA-MB-361 / MDA361 / MDA-361 / MDA 361 / MDA MB 361
- MDAMB415 / MDA-MB415 / MDAMB-415 / MDA-MB-415 / MDA415 / MDA-415 / MDA 415 / MDA MB 415
- MDAMB435 / MDA-MB435 / MDAMB-435 / MDA-MB-435 / MDA-MB-435S / MDA-435 / MDA-435S / MDA435 / MDA435S / MDA 435 / MDA MB 435 / MDA MB 435S
- MDAMB436 / MDA-MB436 / MDAMB-436 / MDA-MB-436 / MDA436 / MDA-436 / MDA 436 / MDA MB 436
- MDAMB453 / MDA-MB453 / MDAMB-453 / MDA-MB-453 / MDA453 / MDA-453 / MDA 453 / MDA MB 453
- MDAMB468 / MDA-MB468 / MDAMB-468 / MDA-MB-468 / MDA468 / MDA-468 / MDA 468 / MDA MB 468
- MFM223 / MFM-223 / MFM 223
- MPE600 / MPE-600 / MPE 600
- MT1 / MT-1 / MT 1
- MT3 / MT-3 / MT 3
- MW
- PMC42 / PMC-42 / PMC 42
- SKBR3 / SKBR-3 / SK-BR3 / SK-BR-3 / SKBR 3 / SK BR 3
- "SUM-series"
- T47D / T47-D / T-47D / T-47-D / T47 D / T 47D / T 47 D
- UACC812 / UACC-812 / UACC 812
- UACC893 / UACC-893 / UACC 893
- UISOBCA1 / UISO-BCA1 / UISO-BCA-1 / UISO BCA1 / UISO BCA 1
- UISOBCA2 / UISO-BCA2 / UISO-BCA-2 / UISO BCA2 / UISO BCA 2
- VHB1 / VHB-1 / VHB 1
- ZR751 / ZR75-1 / ZR-75-1 / ZR75 1 / ZR 75 1
- ZR7530 / ZR75-30 / ZR-75-30 / ZR75 30 / ZR 75 30
To obtain a copy (PDF file) of this paper, please CLICK HERE (Uncorrected proof) or contact the Webmaster..

Webmaster / Webmestre: Marc Lacroix
This page hosted by/Page hébergée par

Get your own Free Home Page /Obtenez votre page personnelle gratuite
Made in BELGIUM / WALLONIA / EUREGIO MAAS-RHINE - Fait en BELGIQUE / WALLONIE / EUREGIO MEUSE-RHIN - (Molecular breast cancer - Cancer du sein, aspects moléculaires) - Marc Lacroix & SciMedWeb® 2004-2009